Zofran
Prostate Carcinoma
Fred Hutchinson Cancer CenterPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
47 Active assets in the Prostate Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Psma-Hbed-Cc Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 | BB |
Olaparib OHSU Knight Cancer Institute | Phase 2 | BB |
Cyclophosphamide OHSU Knight Cancer Institute | Phase 2 | B |
CABAZITAXEL M.D. Anderson Cancer Center | Phase 2 | B |
Pembrolizumab OHSU Knight Cancer Institute | Phase 2 | B |
View all 50 →
Same molecule, other indications
Zofran is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →